Who is impacted?
Millions of patients across the U.S. depend on GLP-1 medications like Tirzepatide (Mounjaro, Zepbound) and Semaglutide (Ozempic, Wegovy) to manage chronic conditions such as type 2 diabetes, obesity, and PCOS. These medications are life-saving for many, helping to prevent severe complications and significantly improving their quality of life. Unfortunately, ongoing shortages and the sky-high cost of brand-name drugs have left countless patients struggling to access the treatments they desperately need, often forcing them to turn to compounding pharmacies for relief.
What is at stake?
If the FDA fails to recognize the ongoing shortages and does not support affordable compounded alternatives, millions of patients will lose access to these critical medications. The potential shutdown of compounding pharmacies—due to regulatory restrictions and pressure from big pharmaceutical companies—will strip away one of the few affordable options available to patients. Without immediate change, people will face declining health, worsening conditions, and overwhelming financial burdens.
Why is now the time to act?
The FDA's recent decisions suggest a troubling prioritization of pharmaceutical profits over patient needs. Shortages are still limiting access, and the cost of brand-name medications remains out of reach for many. Now is the time to stand up for patients who rely on these life-saving drugs. Sign this petition to demand that the FDA prioritize patients by addressing ongoing shortages, supporting compounded alternatives, and ensuring that everyone has access to the treatments they need to live healthy, fulfilling lives.
Sign and share this petition today!
No comments:
Post a Comment